Psoriasis Treatment Market (2025-2032)
The Psoriasis Treatment Market is expected to reach $35.07 billion by 2032, at a CAGR of 9.8% from 2025 to 2032.
- Published
- Jun 2024
- Pages
- 240
- Format
- PDF + Excel
- Report ID
- MR-1225
- Base year
- 2024
- 2032 · FORECAST
- $35.07B
- 2032
- $35.07B
- CAGR 2025–2032
- 9.8%
2024 baseline · 2025–2032 forecast at 9.8% CAGR · hover a bar for the value
Key highlights
By Treatment Type: In 2025, the Biologic Drugs Segment to Dominate the Psoriasis Treatment Market
By Disease Type: In 2025, the Plaque Psoriasis Segment to Dominate the Psoriasis Treatment Market
By Administration Route: In 2025, the Injectable Segment to Dominate the Psoriasis Treatment Market
By Distribution Channel: In 2025, the Hospital Pharmacies Segment to Dominate the Psoriasis Treatment Market
Report summary
| Particulars | Details |
|---|---|
| Page No | 240 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 9.8% |
| Market Size (Value) | $35.07 billion by 2032 |
| Segments Covered | By Treatment Type · Biologic Drugs · TNF Inhibitors · Infliximab · Adalimumab · Etanercept · Other TNF Inhibitors · Interleukin Inhibitors · Guselkumab · Risankizumab · Tildrakizumab · Other Biologic Drugs (Anakinra, Basiliximab, Daclizumab, and Briakinumab, among others) · Topical Treatments · Corticosteroids · Hydrocortisone · Desonide · Betamethasone · Other Corticosteroids · Vitamin D Analogs · Calcitriol · Calcipotriol · Tacalcitol · Retinoids · Calcineurin Inhibitors · Systemic Treatments · Methotrexate · Cyclosporine · Acitretin · Other Systemic Drugs (Apremilast, Cyclosporine, Adalimumab, Ustekinumab, Etanercept, Tofacitinib, and Tildrakizumab, among others) · By Disease Type · Plaque Psoriasis · Psoriatic arthritis · Other Psoriasis Types · (Note: Other Psoriasis Types include Guttate Psoriasis, Pustular Psoriasis, Inverse Psoriasis, Erythrodermic Psoriasis) · By Administration Route · Oral · Topical · Injectable · By Distribution Channel · Hospital Pharmacies · Retail Pharmacies · Online/E-commerce Platforms |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Netherlands, Switzerland, Poland, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, New Zealand, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | AbbVie Inc. (U.S.), AstraZeneca Plc (U.K.), Boehringer Ingelheim (Germany), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson and Johnson (U.S.), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Biogen, Inc. (U.S.), LEO Pharma A/S (Denmark), Sun Pharmaceutical Industries Ltd. (India), and Dr. Reddy’s Laboratories Ltd. (India). |
Report overview
Segments covered: treatment. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market is driven by the high burden of psoriasis, advancements in treatment options, improved psoriasis diagnosis, improved understanding of disease pathogenesis, high rate of elderly people being more susceptible to psoriasis. Moreover, the rising awareness regarding psoriasis, growing use of combination therapies for treatment, and growing research regarding psoriasis are expected to generate growth opportunities for the players operating in the psoriasis treatment market.
Report infographic
Market dynamics
5 factors across 3 forcesHigh Burden of Psoriasis
The burden of psoriasis encompasses a range of physical, emotional, and social challenges for individuals affected by the condition. Psoriasis, a chronic autoimmune disorder, manifests as red, scaly patches on the skin, often accompanied by itching, pain, and discomfort. Beyond its visible symptoms, psoriasis can significantly impact the quality of life, leading to feelings of embarrassment, self-consciousness, and low self-esteem.
The significant impact of psoriasis fuels the growth of the psoriasis treatment market. Affecting millions worldwide, psoriasis causes recurring skin inflammation and lesions, deeply impacting patients both physically and emotionally. According to the National Psoriasis Foundation, around 125 million people, or 2-3% of the global population, are affected by psoriasis. As a chronic condition, psoriasis requires ongoing treatment. The visible symptoms and associated health problems exacerbate the burden for patients. Despite current treatments, many individuals do not experience sufficient relief, indicating a substantial need for better options. Consequently, the extensive global burden of psoriasis drives the adoption of treatment options, propelling the market growth.
Elevated Susceptibility of Elderly Individuals to Psoriasis
The elderly are at a higher risk of developing psoriasis due to various factors. With age, the immune system tends to weaken, leading to less efficient regulation of inflammatory responses, which play a significant role in psoriasis. Moreover, older individuals often contend with other chronic ailments or medications that can either trigger psoriasis or hinder its treatment. Age-related changes in the skin, such as thinning and decreased elasticity, can also heighten susceptibility to psoriasis lesions. Additionally, stress, which may be more prevalent among the elderly due to life transitions and health issues, is a recognized trigger for psoriasis flare-ups. Consequently, the increasing elderly population worldwide is expected to fuel the demand for psoriasis treatment. As per the United Nations, the proportion of individuals aged 65 and above is rising rapidly, with the global percentage projected to escalate from 10% in 2022 to 16% by 2025.
Table of contents
12 chapters · 130 sections · 240 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Treatment Type | Biologic Drugs | Biologics drugs |
| By Disease Type | Plaque Psoriasis | Psoriatic arthritis |
| By Administration Route | Injectable | Consequently, this |
| By Distribution Channel | Hospital Pharmacies | Online/e-commerce platforms |
By Treatment Type
- The Biologic Drugs Segment to Dominate the Psoriasis Treatment Market
- The biologic drugs segment is expected to account for the largest share of 43.7% of the psoriasis treatment market.
- The largest market share of this segment is attributed to their high efficacy and targeted approach in treating moderate to severe psoriasis, ongoing research and development efforts, along increasing adoption by healthcare providers.
- Similarly, the biologics drugs segment is projected to witness the highest growth rate of 7.4% during the forecast period of 2025–2032.
- The expansion of this segment is propelled by the increasing acceptance of Interleukin inhibitors, attributed to their notable effectiveness and favorable safety records.
- As both patients and healthcare providers increasingly favor biologic therapies over conventional systemic medications, coupled with continuous progress in biologic drug innovation, the momentum continues to grow.
- Moreover, the concerted efforts of industry players to introduce new biologic drugs for psoriasis further stimulate the segment's advancement.
- For instance, in March 2024, Eli Lilly and Company (U.S.) unveiled Copellor, an interleukin inhibitor drug designed for psoriasis treatment in India.
By Disease Type
- The Plaque Psoriasis Segment to Dominate the Psoriasis Treatment Market
- The plaque psoriasis segment is expected to account for the largest share of 56.3% of the psoriasis treatment market.
- The large segmental share is attributed to the high prevalence of plaque psoriasis, increasing accuracy in psoriasis, improved diagnostic techniques, growing use of combination therapies, and the launch of new drugs for plaque psoriasis.
- However, the psoriatic arthritis segment is expected to grow at the highest CAGR of 7.1% during the forecast period of 2025-2032.
- Psoriatic arthritis, a form of inflammatory arthritis often accompanying psoriasis, affects approximately 30% of individuals with psoriasis.
- With heightened awareness of this condition and advancements in diagnostic techniques, the demand for treatments addressing psoriatic arthritis is anticipated to rise, thereby fueling the growth of this segment.
By Administration Route
- The Injectable Segment to Dominate the Psoriasis Treatment Market
- The injectable segment is expected to account for the largest share of the psoriasis treatment market.
- This segment is driven by the increasing adoption of biologic therapies, which are mainly administered via injections, advancements in injection technology such as prefilled syringes and autoinjectors, and the expanding availability and accessibility of injectable medications through various distribution channels, including specialty pharmacies and online platforms.
- The increasing adoption of biologic therapies, primarily administered via injections, is driving significant growth within the segment.
- Biologic drugs are highly effective in treating moderate to severe psoriasis, prompting widespread usage by healthcare providers.
- Moreover, advancements in injection technology, including prefilled syringes and autoinjectors, have enhanced patient convenience and comfort, further amplifying the demand for injectable medications.
- Additionally, the escalating prevalence of chronic conditions like psoriasis and psoriatic arthritis necessitates long-term treatment strategies, with injectable therapies often preferred for their consistent dosing and monitoring capabilities.
- Consequently, this segment is poised to exhibit the highest CAGR during the forecast period.
By Distribution Channel
- The hospital pharmacies segment is expected to account for the largest share of the market.
- Hospitals play a pivotal role as primary hubs for diagnosing and treating psoriasis, with hospital pharmacies serving as crucial distribution channels for psoriasis medications.
- These pharmacies typically maintain extensive stocks of medications to meet the diverse requirements of psoriasis patients, encompassing biologic, systemic, and topical treatments.
- Furthermore, healthcare practitioners within hospitals often prescribe medications for acute or severe psoriasis cases, resulting in a heightened volume of prescriptions fulfilled through hospital pharmacies.
- However, the online/e-commerce platforms segment is expected to grow at the highest CAGR during the forecast period.
- The expansion of this market segment can be attributed to the widespread adoption of e-commerce platforms, which have transformed the accessibility of healthcare products for consumers.
- The growing prevalence of digitalization and the convenience of online shopping have further propelled this trend.
- Online platforms provide a vast array of products, enabling patients to compare prices, peruse reviews, and gather information about various treatment options—all from the comfort of their homes.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 43.1% of the psoriasis treatment market. Among the U.S. and Canada, in 2025, the U.S. is expected to account for the largest share of the psoriasis treatment market in North America. The large market share is attributed to the high prevalence of psoriasis, high adoption rate of personalized therapies, well-developed health infrastructure, and continuous research and development for psoriasis, translating into new treatment approaches and drugs.
Asia-Pacific
Fastest growthHowever, Asia-Pacific is slated to register the highest CAGR of 10.2% during the forecast period. The growth of this region is attributed to the rising psoriasis prevalence, growing demand for quality healthcare, shift towards medicine for dermatology conditions from homemade remedies, and a large population base.
Competitive landscape
- November 2024
Lords Mark Biotech (India) launched Tinefcon, a patented medicine for treating Psoriasis.
- November 2024
Amgen Inc. (U.S.) received U.S. FDA approval for a biosimilar version of Johnson & Johnson's (U.S.) psoriasis treatment, Stelara.
- 2024
Biocon Limited (India) entered into an agreement with Biocon Limited Janssen Biotech Inc. (U.S.) and Johnson & Johnson (U.S.) to commercialize Bmab 1200, a biosimilar to Stelara used for treatment in plaque psoriasis in the U.S.
- AbbVie Inc. (U.S.)
- AstraZeneca Plc (U.K.)
- Boehringer Ingelheim · Germany
- Celgene Corporation (U.S.)
- Eli Lilly and Company (U.S.)
- Johnson and Johnson (U.S.)
- Merck KGaA · Germany
- Novartis AG · Switzerland
- Pfizer Inc. (U.S.)
- Takeda Pharmaceutical Company Limited · Japan
- Biogen, Inc. (U.S.)
- LEO Pharma A/S · Denmark
- Sun Pharmaceutical Industries Ltd. · India
- Dr. Reddy’s Laboratories Ltd. · India
Frequently asked questions
The psoriasis treatment market covers the market sizes & forecasts by treatment type, disease type, administration route, and distribution channel. The psoriasis treatment market studied in this report involves the value analysis of various segments and sub-segments of the psoriasis treatment market at regional and country levels.
Cite this report
Meticulous Research. (2024). Psoriasis Treatment Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MR-1225). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/psoriasis-treatment-market-5908